Cyclerion Therapeutics, Inc. (CYCN) is a clinical-stage biopharmaceutical company focused on developing treatments for serious CNS diseases. While its core business activities in biotechnology are permissible under Shariah principles, the company fails financial screening criteria due to high liquidity and interest income ratios. No inclusion in major Shariah indices confirms non-compliance. Purification of 28.55% is required for any impermissible income. Investors should monitor financial restructuring for potential future compliance.